HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Wednesday, 8 December 2010

DSU azacitidine report now public

This work relates to the use of aazacitidine (Vidaza, Celgene) as a treatment option for people with myelodysplastic syndromes and certain other related conditions.  The NICE Decision Support Unit, based within HEDS, were asked to provide a critical appraisal of the evidence submitted by Celgene and the MDS Foundation in response to NICE’s requests following a partially upheld appeal.  A second ACD has now been issued, with the NICE not recommending azacitidine as a treatment option.

For further details contact Sarah Davis.